Cytokinetics, Incorporated

As of June 30, 2026, Cytokinetics, Incorporated carries a market capitalization of 11.82B, placing it among publicly traded companies globally. Its enterprise value stands at 11.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cytokinetics, Incorporated's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Cytokinetics, Incorporated has 138.76M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 156.66, and the price-to-book ratio stands at -68.14.

These figures are as of June 30, 2026. The EV/Sales ratio of 176.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.93B versus a market cap of 11.82B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cytokinetics, Incorporated maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.36, indicating conservative leverage, while an interest coverage ratio of -5.57 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -56.76, reflecting losses generated across the asset base. The company generates approximately 107,540.72 in revenue per employee across its workforce of 629.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Cytokinetics, Incorporated's stock has gained approximately 13.82% over the past 52 weeks. The 50-day moving average sits at 69.17, while the 200-day moving average is 70.14.

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated generated 67.67M in revenue and converted that into -894.00M in net income, yielding earnings per share of -7.18. EBITDA reached -695.36M, while operating income came in at -707.91M.

As of June 30, 2026, Cytokinetics, Incorporated holds 1.17B in cash and equivalents against 1.27B in total debt, resulting in a net debt position of 891.82M. Total book value stands at -173.49M, with working capital of 1.03B providing operational flexibility.

Cytokinetics, Incorporated produced -555.45M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -25.26M in capital expenditures, free cash flow totaled -580.71M - equivalent to -4.67 per share.

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated posted a gross margin of -212.95, reflecting its pricing power and cost economics. The operating margin of -1,046.12 and net profit margin of -1,321.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.50, meaning Cytokinetics, Incorporated raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.

As of June 30, 2026, Cytokinetics, Incorporated has an Altman Z-Score of 0.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.